High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience

Rajendra Bhalavat; Manish Chandra; Vibhay Pareek; Lalitha Nellore; Karishma George; Nandakumar P.; Pratibha Bauskar

doi:10.5114/jcb.2017.67147

eISSN: 2081-2841
ISSN: 1689-832X

Journal of Contemporary Brachytherapy

Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links

Editorial System

Submit your Manuscript

2/2017
vol. 9

Send email

Copy url:

abstract:

Original paper

High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience

Rajendra Bhalavat

,

Manish Chandra

,

Vibhay Pareek

,

Lalitha Nellore

,

Karishma George

,

Nandakumar P.

,

Pratibha Bauskar

J Contemp Brachytherapy 2017; 9, 2: 124–131

DOI: https://doi.org/10.5114/jcb.2017.67147

Online publish date: 2017/04/13

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Bhalavat R, Chandra M, Pareek V, et al. High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience. Journal of Contemporary Brachytherapy. 2017;9(2):124-131. doi:10.5114/jcb.2017.67147.

APA

Bhalavat, R., Chandra, M., Pareek, V., Nellore, L., George, K.,  & P., N. et al. (2017). High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience. Journal of Contemporary Brachytherapy, 9(2), 124-131. https://doi.org/10.5114/jcb.2017.67147

Chicago

Bhalavat, Rajendra, Manish Chandra, Vibhay Pareek, Lalitha Nellore, Karishma George, Nandakumar P.,  and Pratibha Bauskar. 2017. "High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience". Journal of Contemporary Brachytherapy 9 (2): 124-131. doi:10.5114/jcb.2017.67147.

Harvard

Bhalavat, R., Chandra, M., Pareek, V., Nellore, L., George, K., P., N.,  and Bauskar, P. (2017). High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience. Journal of Contemporary Brachytherapy, 9(2), pp.124-131. https://doi.org/10.5114/jcb.2017.67147

MLA

Bhalavat, Rajendra et al. "High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience." Journal of Contemporary Brachytherapy, vol. 9, no. 2, 2017, pp. 124-131. doi:10.5114/jcb.2017.67147.

Vancouver

Bhalavat R, Chandra M, Pareek V, Nellore L, George K, P. N et al. High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience. Journal of Contemporary Brachytherapy. 2017;9(2):124-131. doi:10.5114/jcb.2017.67147.

Purpose: To evaluate the treatment outcomes with high-dose-rate (HDR) interstitial brachytherapy (HDR-BRT) in head and neck cancers (HNC).

Material and methods: Fifty-eight patients with HNC as per American Joint Committee on Cancer (AJCC) TNM staging criteria were analyzed retrospectively between 2008 and 2015. Forty-two patients received external beam radiotherapy (EBRT) with HDR-BRT and 16 patients received BRT alone. The survival was calculated with respect to median biological equivalent doses (BED) and median 2 Gy equivalent dose (EQD₂), keeping / = 10 for tumor. Loco-regional control and disease free survival was assessed.

Results: The median follow-up period was 25 months (2-84 months). The disease-free survival (DFS) probability at year 1 was 82.7%, and 68% at year 7. The overall survival probability was 91.3% at year 1 and 85.8% at year 7. The local control rate was 70%. The rate of recurrence was 30%. Distant metastasis rate was 17.2%. The median BED and EQD₂, respectively, were 86.78 Gy and 71.6 Gy. The DFS was 74.1% and 75.9% in patients receiving a dose more than median BED and EQD₂, respectively, and was 64.8% and 61.5% for less than the median dose.

Conclusions: The overall outcome was good with implementation of HDR-BRT used alone or as boost, and shows DFS as better when the dose received is more than the median BED and median EQD₂. The role of HDR-BRT in HNC is a proven, effective, and safe treatment method with excellent long term outcome as seen in this study, which reflects the need for reviving the forgotten art and science of interstitial brachytherapy in HNC.

keywords:

High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience

Rajendra Bhalavat , Manish Chandra , Vibhay Pareek , Lalitha Nellore , Karishma George , Nandakumar P. , Pratibha Bauskar

BED, EQD2, HDR, head and neck cancer, interstitial brachytherapy

Rajendra Bhalavat

,

Manish Chandra

,

Vibhay Pareek

,

Lalitha Nellore

,

Karishma George

,

Nandakumar P.

,

Pratibha Bauskar

BED, EQD₂, HDR, head and neck cancer, interstitial brachytherapy